tbuckley/cabot-search huggingface dataset:
Active management of labour.
Authors: D Tacchi
Journal: BMJ (1972)

officer and makes it sound more attractive to experienced ward sisters.But the report fails to consider the prospects for those who wish to remain ward sisters.This omission must be remedied and various suggestions have been floated.For instance, to prevent no.6s just "drifting into administration" they might be paid at no. 7 rates.16It has also been proposed that no.6s should be promoted to no. 7s after seven years, and after 15 years to no. 8s.17Another idea has been to introduce "clinical nurse consul- tants."3 18There are, no doubt, other practicable solutions but a satisfactory answer to this dilemma is urgent.Nearly a year ago the chairman of the Royal College of Nursing's working partly on the subject invited further suggestions from readers of the B.M.7.19 Meanwhile a Scottish working party, chaired by Dame Muriel Powell (Chief Nursing Of- ficer for Scotland), hopes that the forthcoming reorganization of the Health Service will encourage the long overdue re- cognition of specialist nursing skills (the province of the ward sister) and also the importance of nursing research.20Sir George Godber's working party on the organization of medical work in hospitals, whose Cogwheel report appeared in 1967,21 has remained in being, monitoring the results of its recommendations and reporting again this year.22Progress on Salmon is the only other commentary yet to appear on the effects of the many reports and recommendations on health services in recent years.Would it have read differently if the Salmon team had survived to probe the report's outcome, and how quickly might its members have spotted that missing prong?
A Prospective Cohort Study of the Epidemiology of Symptomatic Venous Thromboembolism (VTE) after Isolated Leg Fractures Distal to the Knee without Thromboprophylaxis.
Authors: Rita Selby, William H. Geerts, Mark A. Crowther, Hans J. Kreder, Maurice Bent, Emil Schemitsch, Peter Weiler
Journal: Blood (2004)
Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells
Authors: Sonam Dolma, Hayden J. Selvadurai, Xiaoyang Lan, Lilian Lee, Michelle Kushida, Veronique Voisin, Heather Whetstone, Milly So, Tzvi Aviv, Nicole Park, Xueming Zhu, ChangJiang Xu, Renee Head, Katherine J. Rowland, Mark Bernstein, Ian D. Clarke, Gary Bader, Lea Harrington, John H. Brumell, Mike Tyers, Peter B. Dirks
Journal: Cancer Cell (2016)
Unplanned hospital admission of early breast cancer outpatients treated with adjuvant chemotherapy
Authors: C. Bozza, C. Fontanella, V. Fanotto, E. De Carlo, D. Iacono, M. Bonotto, M. Cinausero, L. Gerratana, M. Guardascione, K. Rihawi, S. Russo, C. Andreetta, A.M. Minisini, S. Moroso, M. Mansutti, G. Aprile, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2015)
Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions
Authors: Gabriela Soriano Hobbs, Patrick Hilden, Amir Hamdi, Jenna D Goldberg, Michelle Poon, Celina Ledesma, Sean Devlin, Gabriela Rondon, Esperanza B. Papadopoulos, Ann A. Jakubowski, Richard J. O'Reilly, Richard E Champlin, Sergio A Giralt, Partow Kebriaei, Miguel Angel Perales
Journal: Blood (2013)
Place of double half-body irradiation in the treatment of multiple myeloma?
Authors: X Troussard, M Leporrier
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.12.2233 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1960564 Place of double half-body irradiation in the treatment of multiple myeloma? X TroussardxX TroussardSearch for articles by this author , M LeporrierxM LeporrierSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.12.2233 First Page PDF © 1991 by American Society of Clinical Oncology
A Framework Action Plan to fight Tuberculosis in the European Union
Authors: K Fernandez de la Hoz, D Manissero, None on behalf of the Tuberculosis Disease Programme*
Journal: Eurosurveillance (2008)

Many European Union (EU) Member States show a decline in tuberculosis (TB) incidence and many have low incidence rates (15 countries reported less than 10 cases per 100,000 population in 2006). However, despite the progress in curbing the TB epidemic, the disease remains a public health threat in the EU. The epidemiological patterns are still very diverse between countries and control efforts are challenged by problems such as multidrug-resistant (MDR TB) and extensively drug-resistant tuberculosis (XDR TB), TB/HIV co-infection and the concentration of cases within vulnerable groups.
Outbreak of cryptosporidiosis in a child day-care centre in Gipuzkoa, Spain, October to December 2011
Authors: J Artieda, M Basterrechea, L Arriola, M Yagüe, E Albisua, N Arostegui, U Astigarraga, R Botello, J M Manterola
Journal: Eurosurveillance (2012)

From October to December 2011, an outbreak of 26 cases of cryptosporidiosis occurred in a day-care centre in Gipuzkoa, Spain. The infection spread from person to person and affected 24 children under two years of age (attack rate: 38%) and two caregivers. Cryptosporidium oocysts were observed in 10 of 15 samples. During 2010, only four cases of cryptosporidium were detected in Gipuzkoa, and 27 overall in Spain.
Case 4-1981
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Raymond S. Koff, James J. Galdabini
Journal: New England Journal of Medicine (1981)

Presentation of CaseA 26-year-old woman was admitted to the hospital because of increasing jaundice and impending labor.She was well until two and a half weeks earlier, when symptoms of an upper-respiratory-tract infection developed during the 30th week of her first pregnancy and were followed by headache, anorexia, nausea, and vomiting. She consulted a physician, who prescribed amoxicillin. She took two doses, but vomiting persisted; she entered another hospital, where fluids were administered by vein. Vomiting continued, and three days before admission to this hospital jaundice was observed. The prothrombin time was 19 seconds, with a control of 13 . . .
Database is linked to Read codes
Authors: R. Weeks
Journal: BMJ (1996)

will be made available to vendors of general practitioner and hospital software for incorporation in their systems, whether on DOS or other platforms.Copies of the BNF are purchased by the Department of Health in bulk and then provided free to doctors and pharmacists working for the NHS.No such arrangement exists at present for the electronic version, which is available only through the publishers (BMA and the Royal Pharmaceutical Society ofGreat Britain).The stand alone eBNF runs adequately on personal computers with a 386 processor, though a more powerful processor and more memory will increase its speed.The stand alone eBNF is run from the hard disk.Most new non-clinical software that clinicians may want to use runs under Win- dows; users are therefore likely to replace their systems with newer hardware that will run such software.
TB-08MECHANISMS OF IMMUNE RESISTANCE IN PEDIATRIC POSTERIOR FOSSA TUMORS
Authors: William Brugmann, Alvaro Laureano, Jonathan Torchia, Rashieda Hatcher, Bridget Kennis, Soumen Khatua, Wafik Zaky, Gianluca Sbardella, Judy Moyes, Stewart Goldman, Rishi Lulla, Jason Fangusaro, David Sandberg, Lucia Silla, Veena Rajaram, Cynthia Hawkins, Annie Huang, Laurence Cooper, Dean Lee, Vidya Gopalakrishnan
Journal: Neuro-Oncology (2016)

TB-08. MECHANISMS OF IMMUNE RESISTANCE IN PEDIATRIC POSTERIOR FOSSA TUMORS William Brugmann1, Alvaro Laureano2, Jonathan Torchia5, Rashieda Hatcher1, Bridget Kennis1, Soumen Khatua1, Wafik Zaky1, Gianluca Sbardella3, Judy Moyes1, Stewart Goldman4, Rishi Lulla4, Jason Fangusaro4, David Sandberg7, Lucia Silla2, Veena Rajaram6, Cynthia Hawkins5, Annie Huang5, Laurence Cooper1, Dean Lee1, and Vidya Gopalakrishnan1; University of Texas MD Anderson Cancer Center, Houston, TX, USA; Hospital de Clinicas de Porto Alegre, Porto Allegre, Brazil; Universita di Salerno, Fisciano, Salerno, Italy; Lurie Children’s Hospital, Northwestern University, Chicago, IL, USA; Hospital for Sick Children, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX, USA; Universityof TexasatHouston, Houston, TX, USA Posterior fossa tumors (PFT) such as medulloblastoma (MB) and atypical teratoid rhabdoid tumor (ATRT) are aggressive and malignant pediatric brain tumors. Tumor recurrence is common with no available cure. The current standard-of-care can cause significant morbidities including a sharply elevated risk for secondary malignancies, ototoxicity and neurophysiological sequelae.Here,weofferanewtherapeutic approach forchildrenwith recurrent/refractory PFT,which harnesses the killing capacity of naturalkiller (NK) cells. This is predicated on our ability to deliver ex vivo expanded and activated clinical grade NK cells to the tumor microenvironment through an ommaya reservoir. In pre-clinical studies we observed that many MBs and ATRT were susceptible to NK cells in vitro and in vivo. These observations provided support for a first in humans Phase I trial (NCT02271711) to examine the safety and feasibility of infusing NK cells into the fourth ventricle of patients with recurrent/refractory PFTs. Our in vitro studies also identified resistance to NK-mediated lysis in a subset of MBs and ATRTs. This resistance was caused by the epigenetic upregulation of the growth and differentiation factor-1 (GDF-1), a member of the TGF-beta family, in ATRTs and the elevated expression of the programmed death-ligand 1 (PD-L1) in MBs. Their genetic and pharmacological manipulation countered tumor cell resistance to cytolysis by NK cells. Mis-regulation of these molecules was also observed in patient samples, setting the stage for their development as biomarkers to predict tumor response, and providing justification for subsequent clinical trials combining NK cells with epigenetic modifiers. Neuro-Oncology 18:iii169–iii173, 2016. doi:10.1093/neuonc/now084.5 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders
Authors: J R Sands, M Harrow
Journal: American Journal of Psychiatry (1994)

The current research was designed to investigate the relationship between affective disruption and psychosis in unipolar major depressive disorder and to evaluate whether some depressed patients are particularly vulnerable to subsequent psychosis.A group of 31 psychotic and 63 nonpsychotic inpatients with unipolar depression were assessed during hospitalization and then prospectively assessed for depressive and psychotic symptoms 2.4 years after hospital discharge.The psychotic depressed inpatients had significantly higher rates of psychosis during the posthospital period, 2.4 years later, than the originally nonpsychotic depressed inpatients. However, they did not have higher rates of depressive syndromes during the posthospital period. Psychosis during the posthospital period was significantly related to recurrent or persistent affective disruption. The posthospital depressive syndromes of the initially psychotic depressed inpatients tended to be slightly more severe than those of the initially nonpsychotic depressed inpatients. Despite this, psychosis during the inpatient period was more predictive of posthospital psychosis than the severity of the posthospital depressive syndrome.The interaction of the following two factors was proposed to be central to psychotic depression: 1) a vulnerability to psychosis, and 2) concurrent affective disruption.
CE-LIF analysis of endogenous DNA damage in mitochondrial DNA
Authors: Oliver Johannes Schmitz, Michaela Wirtz, Claus A. Schumann, Siegmar Gäb, Jochen Vom Brocke, Michael Alois L. Podeschwa, Hans-Josef Altenbach
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

1539 

Reactive oxygen molecules, in the forms of superoxide, hydrogen peroxide, and hydroxyl radicals, are formed in vivo as byproducts of normal aerobic metabolism, so that all organisms dependent on oxygen are inevitably exposed to these species. Because of the proximity of mitochondrial DNA (mtDNA) to the mitochondrial electron transport chain, the lack of protective histons and the less efficient DNA repair in mitochondria, it is of interest to determine DNA damage from oxidative stress in the mtDNA. We have developed and validated an analysis of mtDNA modifications that involves the isolation and hydrolysis of mtDNA, the labeling of modified and unmodified nucleotides (as well as 2′-deoxyribose-3′-phosphate) with BODIPY® FL EDA as fluorescence marker, and micellar electrokinetic chromatography with laser-induced-fluorescence detection (CE-LIF). The derivatization reaction was characterized by spectroscopy (ESI-MS, 1H-, 13C-, 11B- and 19F-NMR) of the 2′-deoxyadenosine-3′-monophosphate-BODIPY® FL EDA conjugate. We have identified etheno-adenosine, 8-oxo-guanosine and 5-methylcytosine by addition of internal standards to the mtDNA. There are a large number of other signals in the electropherograms of mtDNA that we have never found in genomic DNA analysis because they are at lower concentration in the genome. Therefore we have developed a new strategy to synthesize further modified nucleotides with the necessary phosphate moeity in the 3′-position of the 2′-deoxyribose. So far, we have tried to identify the other DNA modifications with these newly synthesized and characterized standards. Literature assertions about the content of 5-methylcytosine in mtDNA are very inconsistent, and we suspect the concentration is near or equal to zero, for which reason we are using 5-methylcytosine as a marker for contamination by genomic DNA.
The Impact of Normal Volunteers on a Psychiatric Research Unit
Authors: Philip Gold, Yolande B. Davenport, Thomas Wehr, Frederick K. Goodwin
Journal: American Journal of Psychiatry (1979)

Normal subjects were admitted to a psychiatric unit devoted to the study and treatment of affective illness. Initially the authors were concerned about the difficulties volunteers might have living with psychiatric patients. However, the volunteers adjusted with relative ease, while the patients' depressive symptoms were exacerbated. Their confrontation with the volunteers' "normality" triggered an acute awareness of their underlying sense of failure. This response is analogous to depressed patients' reactions before discharge, when they struggle not only with their special vulnerability to separation and loss but with inevitable challenges to their fragile self-esteem during reintegration into the outside world. The presence of normal volunteers highlighted these issues and led to increased therapeutic work and considerable resolution.
Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: a 16-year update
Authors: K S Kendler, C D Robinette
Journal: American Journal of Psychiatry (1983)

The authors present a 16-year update on schizophrenia in the National Academy of Sciences-National Research Council (NAS-NRC) Twin Registry. As of October 1981, a recorded diagnosis of schizophrenia was equally common in monozygotic and dizygotic twins. However, probandwise concordance for schizophrenia was significantly greater in monozygotic (30.9%) than in dizygotic (6.5%) twins. Biases in zygosity determination, diagnosis, or ascertainment could not plausibly explain these results. Correction for selection effects in construction of the registry produced concordance rates for schizophrenia approaching those found in previous studies. According to registry data, genetic factors appear at least as important in the etiology of schizophrenia as in several common medical conditions, including diabetes and hypertension. Results from the NAS-NRC Twin Registry support the etiologic importance of genetic factors in schizophrenia.
New influenza A(H1N1) virus infections in France, April – May 2009
Authors: Collective New influenza A(H1N1) investigation teams*
Journal: Eurosurveillance (2009)

Since the emergence of a new influenza A(H1N1) virus in North America and its international spread, an active surveillance of cases of infection due to this virus has been set up in France in order to undertake appropriate measures to slow down the spread of the new virus. This report describes the epidemiological and clinical characteristics of the 16 laboratory confirmed cases diagnosed in France as of 20 May 2009.
Correspondence Structure, stress and tissue repair in aortic valve leaflets
Authors: A Trowbridge, C Crofts
Journal: Cardiovascular Research (1988)

Journal Article Correspondence Structure, stress and tissue repair in aortic valve leaflets Get access Cardiovascular Research, Volume 22, Issue 10, October 1988, Page 746, https://doi.org/10.1093/cvr/22.10.746 Published: 01 October 1988
Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response
Authors: E. H. Kraut, M. N. Fishman, P. M. Lorusso, M. S. Gordon, E. H. Rubin, A. Haas, G. J. Fetterly, P. Cullinan, J. L. Dul, J. L. Steinberg
Journal: Journal of Clinical Oncology (2005)

2017 Background: The prodrug irinotecan is converted into its active moiety, SN-38, with wide interpatient variability, due in part to differential expression of cellular carboxylesterases responsible for prodrug hydrolysis. The enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) detoxifies SN-38 by metabolizing it to SN-38 glucuronide. Polymorphisms in the UGT1A1 promoter lead to decreased expression of the enzyme and are associated with increased risk of irinotecan toxicity. Methods: This was a multi-center, dose-escalation study of Liposome Encapsulated SN-38 (LE-SN38) in patients with advanced cancer. To examine whether toxicities and appropriate dose levels might differ with UGT1A1*28 genotype, patients were stratified prospectively. LE-SN38 was infused intravenously over 90 minutes every 21 days until disease progression or unacceptable toxicity occurred. Tumor progression was monitored radiographically after every 2 cycles. Results: Enrollment is complete; 75 patients were treated with LE-SN38. Screened patients had genotype frequencies of 42.4% homozygous wild-type (WT/WT), 45.1% heterozygous (WT/*28), 10.9% homozygous variant (*28/*28), and 1.6% other. Across all genotypes the most frequent adverse events were fatigue, nausea, anorexia, diarrhea, and vomiting. Importantly, diarrhea was generally mild and self-limiting, and no late onset diarrhea was reported. DLTs of neutropenia/febrile neutropenia in WT/WT patients at 40 mg/m2 resulted in an MTD of 35 mg/m2. No DLTs occurred in *28/*28 patients; accrual was halted at 20 mg/m2 before the MTD was reached. PK results showed that *28/*28 patients had 2- to 3-fold greater drug exposure than WT/*28 or WT/WT patients at the same doses. Stable disease (≥4 cycles) was observed in 37% of patients. Conclusions: LE-SN38 was well tolerated in all patients, with no reported acute/delayed diarrhea. The MTD was not reached for *28/*28 patients. An MTD of 35 mg/m2 LE-SN38 was found for WT/WT patients. Since WT/WT and WT/*28 patients did not appear to exhibit clinically significant differences in safety or PK profiles, this dose will be evaluated in both groups in a Phase II study of patients with colon cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration NeoPharm
LG-72CYST RESPONSE TO BEVACIZUMAB IN PILOCYTIC ASTROCYTOMA: A CASE SERIES
Authors: Rachel Gray, Ana Aguilar-Bonilla, Emily Owens Pickle, Amy Smith
Journal: Neuro-Oncology (2016)

Pilocytic astrocytoma (PA) is one of the most common central nervous system (CNS) tumors in childhood, accounting for 21-23% of all pediatric CNS tumors.PA is a low grade glioma often characterized by solid and cystic components.Current treatment strategies include surgery, chemotherapy, and/or radiation.Although chemotherapy and radiation are effective against the solid component, they show limited activity on the cystic
Incidentally Detected Sigmoidovesical Fistula in a Case of Rectosigmoid Cancer Detected on FDG PET-CT
Authors: Chidambaram Natrajan Balasubramanian Harisankar
Journal: Clinical Nuclear Medicine (2015)

Enterovesical fistulas are complications of advanced pelvic malignancies, repeated diverticulitis, and rare conditions like Crohn disease. They are difficult to demonstrate on conventional imaging and often are the source of recurrent urinary tract infections. An interesting case of sigmoidovesical fistula secondary to advanced rectosigmoid cancer is described in this case report.
Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women
Authors: Hsu-Chih Chien, Yea-Huei Kao Yang, Jane P. F. Bai
Journal: JAMA Oncology (2016)

Trastuzumab is an essential medicine per the World Health Organization Model List, but its cardiac safety information in Asian women is limited.To estimate the rate and the risk of heart failure (HF) and/or cardiomyopathy (CM) in Asian women undergoing trastuzumab treatment.This cohort study used the Taiwanese National Health Insurance Research Database (NHIRD), a nationwide claim database covering more than 99% of the entire Taiwanese population, to identify 23 006 women with incident breast cancer (BC) who received chemotherapy from 2006 to 2009. We grouped women per their initial treatment regimens and found 1066 new trastuzumab users. We matched trastuzumab users with nonusers by year of BC diagnosis and propensity score (PS) with the caliper widths at 0.25 standard deviation of PS (up to 4 nonusers per trastuzumab user). The study lasted from January 2006 to December 2013 with a median follow-up of 5.29 years and a landmark design to avoid immortal time bias.Trastuzumab.To estimate HF and/or CM rates and time to HF and/or CM, we employed a cause-specific hazard model. Trastuzumab exposure was a time-dependent variable, while cumulative courses of chemotherapy agents with known cardiotoxic effects (including anthracyclines, taxanes, and cyclophosphamide) were defined as time-dependent covariates in the analysis model. We also performed 6 sensitivity analyses.In this cohort of 23 006 women (mean age, 50.99 years), the crude incidence of HF and/or CM was 4.03% in trastuzumab users and 2.88% in nonusers. The median time to HF and/or CM was 456 days in trastuzumab users and 966 days in nonusers. The 1-year cumulative hazard ratio was 1.86 (95% CI, 1.08-3.19). The sensitivity analyses yielded similar results.Compared with the published results, the trastuzumab-related HF and/or CM rate was 5-fold lower in Taiwanese women with breast cancer. Nonetheless, our cohort had a similar trastuzumab-related HF and/or CM risk. Our study provides critical cardiac safety information of trastuzumab for Asian women with BC under current treatment guidelines and label information.